Hepatitis B and C infection in tuberculosis patients in the Hauts Bassins region of Burkina Faso, West Africa

Tuberculosis (TB) and viral hepatitis B and C represent significant public health concerns. Co-infection with TB and hepatitis B and/or C results in significant complications, including suboptimal treatment outcomes in TB and the development of hepatitis induced by anti-TB drugs. At present, no data...

Full description

Saved in:
Bibliographic Details
Main Authors: Armel Moumouni Sanou, Abdoulaye Dera, Jeoffray Diendere, Nina Mathuola Geneviève Ouattara, Eric Kyelem, Arhouna Siguina Traore, Arouna Dao, Arielle Sandra Bettina Badiel, Ina Marie Angèle Traore, Michel Kiréopori.B Gomgnimbou, Isidore Bonkoungou, Gautier Henri Ouedraogo
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Journal of Clinical Virology Plus
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667038025000109
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tuberculosis (TB) and viral hepatitis B and C represent significant public health concerns. Co-infection with TB and hepatitis B and/or C results in significant complications, including suboptimal treatment outcomes in TB and the development of hepatitis induced by anti-TB drugs. At present, no data on these co-infections are available for Burkina Faso. This study investigates the epidemiology of these co-infections in TB patients in the Hauts-Bassins region of Burkina Faso. A cross-sectional analytical study was conducted in health facilities involved in the management of TB in the Hauts-Bassins region of Burkina Faso from October 2023 to June 2024. For each consenting TB patient, data were collected. A blood sample was obtained and analyzed for a range of infection markers (HBsAg, HBV DNA, anti-HCV antibodies, and HCV RNA) and liver enzymes (ALT and γ-GT). A total of 259 TB patients were included in the study. The mean age of the participants was 39.7 ± 15.9 years. The overall prevalence of HBsAg was 10.03 % and 3.8 % for anti-HCV. Among the HBsAg-positive samples, HBV DNA was detected in all cases, with 68.2 % exhibiting a viral load exceeding 20,000 IU/mL. Elevated ALT was observed in 19.2 % of TB/HBsAg patients and in 30.0 % of TB/anti-HCV. About γ-GT, an elavated result was observed in 46.1 % of TB/HBsAg patients and 40.0 % of TB/anti-HCV patients. The results demonstrated a high prevalence of hepatitis B and intermediate exposure to HCV in TB patients. It is thus recommended that routine screening for these diseases be considered in TB patients.
ISSN:2667-0380